Compositions and methods for the reduction or prevention of hepatic steatosis
First Claim
Patent Images
1. A method of reducing non-alcoholic steatohepatitis (NASH) in a subject in need thereof, comprising administering to the subject a composition comprising:
- a) an amount of leucine in the form of a free amino acid and/or metabolite thereof;
b) an amount of metformin; and
c) an amount of sildenafil;
wherein the amount of component (a) administered to the subject is about 0.25-3 g/day of leucine in the form of a free amino acid, and/or about 0.2-3 g/day of leucine metabolite;
wherein the amount of component (b) administered to the subject is about 10-1000 mg/day of metformin;
wherein the amount of component (c) administered to the subject is about 0.05-100 mg/day of sildenafil; and
wherein components (a), (b), and (c) are co-administered to the subject simultaneously as a single composition or sequentially.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.
-
Citations
22 Claims
-
1. A method of reducing non-alcoholic steatohepatitis (NASH) in a subject in need thereof, comprising administering to the subject a composition comprising:
-
a) an amount of leucine in the form of a free amino acid and/or metabolite thereof; b) an amount of metformin; and c) an amount of sildenafil; wherein the amount of component (a) administered to the subject is about 0.25-3 g/day of leucine in the form of a free amino acid, and/or about 0.2-3 g/day of leucine metabolite; wherein the amount of component (b) administered to the subject is about 10-1000 mg/day of metformin; wherein the amount of component (c) administered to the subject is about 0.05-100 mg/day of sildenafil; and wherein components (a), (b), and (c) are co-administered to the subject simultaneously as a single composition or sequentially. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 17, 18, 19, 20, 21, 22)
-
-
14. A method of treating non-alcoholic steatohepatitis (NASH) in a subject in need thereof, comprising administering to the subject a composition comprising:
-
a. an amount of leucine in the form of a free amino acid and/or metabolite thereof; b. an amount of metformin; and c. an amount of sildenafil; wherein the amount of component (a) administered to the subject is about 0.25-3 g/day of leucine in the form of a free amino acid, and/or about 0.2-3 g/day of leucine metabolite; wherein the amount of component (b) administered to the subject is about 10-1000 mg/day of metformin; wherein the amount of component (c) administered to the subject is about 0.05-100 mg/day of sildenafil; and wherein components (a), (b), and (c) are co-administered to the subject simultaneously as a single composition or sequentially. - View Dependent Claims (15, 16)
-
Specification